HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

T Oguri Selected Research

Malignant Pleural Effusion

10/2001Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


T Oguri Research Topics

Disease

6Lung Neoplasms (Lung Cancer)
11/2001 - 04/2000
6Urinary Tract Infections (Urinary Tract Infection)
06/2001 - 04/2000
5Neoplasms (Cancer)
08/2001 - 01/2000
3Infections
07/2001 - 04/2000
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2017 - 12/2016
2Communicable Diseases (Infectious Diseases)
07/2001 - 05/2000
2Chronic Bronchitis
07/2001 - 05/2000
2Respiratory Tract Infections (Respiratory Tract Infection)
07/2001 - 06/2000
1Asthma (Bronchial Asthma)
11/2017
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
12/2016
1Interstitial Lung Diseases (Interstitial Lung Disease)
08/2002
1Inappropriate ADH Syndrome (SIADH)
10/2001
1Adenocarcinoma
10/2001
1Malignant Pleural Effusion
10/2001
1Respiratory Insufficiency (Respiratory Failure)
12/2000
1Heart Valve Diseases (Valvular Heart Disease)
12/2000
1Bacterial Infections (Bacterial Infection)
06/2000
1Bacterial Pneumonia
05/2000
1Squamous Cell Carcinoma of Head and Neck
01/2000

Drug/Important Bio-Agent (IBA)

6Anti-Infective Agents (Microbicides)IBA
06/2001 - 04/2000
4Carboplatin (JM8)FDA LinkGeneric
11/2001 - 04/2000
4PlatinumIBA
08/2001 - 01/2000
4Pharmaceutical PreparationsIBA
08/2001 - 01/2000
3Multidrug Resistance-Associated ProteinsIBA
08/2001 - 01/2000
3Anti-Bacterial Agents (Antibiotics)IBA
07/2001 - 05/2000
2NivolumabIBA
11/2017 - 12/2016
2EnzymesIBA
11/2001 - 07/2000
2Cisplatin (Platino)FDA LinkGeneric
10/2001 - 04/2000
2Messenger RNA (mRNA)IBA
08/2001 - 01/2000
2multidrug resistance-associated protein 1IBA
08/2001 - 04/2000
2XenobioticsIBA
08/2000 - 04/2000
2Type I DNA Topoisomerases (Topoisomerase I)IBA
07/2000 - 01/2000
1Indicators and Reagents (Reagents)IBA
08/2002
1gamma-glutamylcysteineIBA
11/2001
1Glutathione (Reduced Glutathione)IBA
11/2001
1Ligases (Synthetase)IBA
11/2001
1Vasopressins (Vasopressin)IBA
10/2001
1Vindesine (Vindesin)IBA
10/2001
1Glucose (Dextrose)FDA LinkGeneric
08/2001
1Cytochrome P-450 CYP3AIBA
07/2001
1Docetaxel (Taxotere)FDA Link
07/2001
1cytochrome P-450 CYP2C subfamilyIBA
07/2001
1Oxygen (Dioxygen)IBA
12/2000
1Glutathione S-Transferase piIBA
08/2000
1Irinotecan (Camptosar)FDA LinkGeneric
07/2000
1FluoroquinolonesIBA
06/2000
1Multidrug Resistance-Associated Protein 2IBA
01/2000
1Proteins (Proteins, Gene)FDA Link
01/2000
1Biological ProductsIBA
01/2000
1trioctyl phosphine oxide (TOPO)IBA
01/2000

Therapy/Procedure

2Drug Therapy (Chemotherapy)
10/2001 - 07/2001
2Indwelling Catheters (Indwelling Catheter)
05/2001 - 04/2000
2Therapeutics
12/2000 - 01/2000
1Operative Surgical Procedures
05/2001